I think Misui’s point is the company SEEMS to be

I think Misui’s point is the company SEEMS to be slower than she and myself would prefer on getting trials moving forward. Of course, we don’t know some things because our “partners “ may not be operating under the same expectations we have as investors in a publicly traded company.

I love they have/are getting the basket trial data fixed and presented in what seems to be a positive light for LL effectiveness. It doesn’t keep me wondering about the current clinical progress. Why is the CRC trial taking so long to get kicked off? I’d love a PR informing us more about this key trial. Are we an oncology company or not!